GFR — One of the most important markers for identifying impaired renal function
Currently, GFR is based on an estimation using clinical data and blood-based biomarkers, like creatinine or cystatin C. GFR can either be measured (mGFR) by tracer methods or estimated (eGFR).
mGFR methods are elaborate and time-consuming, and eGFR lacks accuracy in a number of common clinical situations. Because of this, clinical decision-making is difficult, especially early when intervention may help slow progression to end-stage renal disease.
1. 2011–2014 National Health and Nutrition Examination Survey and the CKD Epidemiology Collaboration (CKD-EPI) equation.
Numares developed a novel multi-parametric serum test called AXINON®GFR(NMR) to assess kidney function and significantly improve on the current standard of serum creatinine-based estimated Glomerular Filtration Rate (eGFR).
Our NMR (nuclear magnetic resonance)-based early GFR data determination is more accurate than creatinine-based, conventional eGFR and comparable to tracer-based mGFR methods.
Using the metabolomics approach and Numares’ Magnetic Group Signaling (MGS®) technology, evaluating NMR-based GFR biomarkers yields defined metabolite constellations displaying impaired GFR.
AXINON® GFR(NMR) can improve patient care by offering an accurate, easy way to assess renal function, monitor disease progression and track therapies with nephrotoxic drugs.
AXINON® System GFR(NMR) produces high-quality test results — standardized NMR spectra based on our Magnetic Group Signaling (MGS®) technology.
MGS® with the AXINON® System allows for test-specific spectral analysis with highly reproducible results.
To date, more than 2 million tests have been performed worldwide, using the Numares technology.
* For Research Use only in the United States. numares’ products are not yet available for sale within the United States; they have not yet been approved or cleared by the U.S. Food and Drug Administration.